$1.03
1.90% today
Nasdaq, Sep 18, 09:11 pm CET
ISIN
IL0011319527
Symbol
ENLV

Enlivex Therapeutics Ltd Stock price

$1.05
-0.20 16.00% 1M
-0.10 8.70% 6M
-0.12 10.26% YTD
-0.46 30.46% 1Y
-3.65 77.66% 3Y
-4.17 79.89% 5Y
-256.95 99.59% 10Y
-334.95 99.69% 20Y
Nasdaq, Closing price Wed, Sep 17 2025
-0.03 2.78%
ISIN
IL0011319527
Symbol
ENLV
Industry

Key metrics

Basic
Market capitalization
$25.1m
Enterprise Value
$5.5m
Net debt
positive
Cash
$19.5m
Shares outstanding
23.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
85.2%
Return on Equity
-63.7%
ROCE
-78.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-14.8m | -
EBIT
$-15.2m | $-14.3m
Net Income
$-13.1m | $-14.2m
Free Cash Flow
$-12.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
17.2% | -
EBIT
18.6% | 8.1%
Net Income
41.2% | 5.1%
Free Cash Flow
26.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.5
Short interest
1.2%
Employees
71
Rev per Employee
$0.0
Show more

Is Enlivex Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Enlivex Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Enlivex Therapeutics Ltd forecast:

Buy
88%
Hold
13%

Financial data from Enlivex Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.72 4.72
6% 6%
-
- Research and Development Expense 10 10
23% 23%
-
-15 -15
17% 17%
-
- Depreciation and Amortization 0.37 0.37
51% 51%
-
EBIT (Operating Income) EBIT -15 -15
19% 19%
-
Net Profit -13 -13
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about Enlivex Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enlivex Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
7 days ago
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients       Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Neutral
GlobeNewsWire
9 days ago
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Neutral
GlobeNewsWire
about one month ago
ENX-CL-05-001 Trial: 3-months topline data -   In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% improvement in knee function, were observed in the AllocetraTM treatment arm vs placebo; moreover, 72% reduction in knee pain and 95% improvement in knee function were observed for age-...
More Enlivex Therapeutics Ltd News

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Head office Israel
CEO Dr. Hershkovitz
Employees 71
Founded 2012
Website www.enlivex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today